Diversity & Inclusion Through The Eyes Of Two Female Pharma Executives

By Blandine Lacroix, Petra Molan, and Dan Schell

In recent years we’ve seen more and more companies stressing the need for better diversity and inclusion (D&I) in life sciences. That not surprising, considering the lack of D&I in this industry has been a longstanding and well-known issue. It’s also an issue that has multiple facets. For example, sometimes these discussions are focused on the lack of D&I in clinical trials and how that can negatively affect overall therapeutic outcomes. Then there’s the concern over the lack of D&I among boards or leadership in general. And finally, there’s the need for a more diverse and inclusive workforce, and how such a composition can lead to more business success.

Search our website and you’ll find multiple articles, podcasts, and executive virtual roundtables (video) related to the various aspects of D&I. Much of that content includes tangible ways you can improve D&I in your organization. In the following, we present two first-hand accounts of what it has been like to be a woman working in the pharma industry for many years, and what we can do to overcome this industrywide challenge and continue to push us forward.